178 related articles for article (PubMed ID: 15517895)
1. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
Wigington DP; Urben CM; Strugnell SA; Knutson JC
Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells.
Wigington DP; Strugnell SA; Knutson JC
Anticancer Res; 2005; 25(3B):1909-17. PubMed ID: 16158925
[TBL] [Abstract][Full Text] [Related]
3. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
4. 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors.
Zinser GM; Tribble E; Valrance M; Urben CM; Knutson JC; Mazess RB; Strugnell SA; Welsh J
Anticancer Res; 2005; 25(1A):235-41. PubMed ID: 15816543
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug.
Wang YR; Wigington DP; Strugnell SA; Knutson JC
Anticancer Res; 2005; 25(6B):4333-9. PubMed ID: 16309237
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Tyagi AK; Agarwal C; Chan DC; Agarwal R
Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
[TBL] [Abstract][Full Text] [Related]
7. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.
Levy Y; Knutson JC; Bishop C; Shany S
Anticancer Res; 1998; 18(3A):1769-75. PubMed ID: 9673403
[TBL] [Abstract][Full Text] [Related]
8. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
Vadgama JV; Wu Y; Shen D; Hsia S; Block J
Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
[TBL] [Abstract][Full Text] [Related]
9. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
10. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
Gavrilov V; Steiner M; Shany S
Anticancer Res; 2005; 25(5):3425-9. PubMed ID: 16101159
[TBL] [Abstract][Full Text] [Related]
11. [Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines].
Akutsu M; Suzuki K; Tsunoda S; Kano Y
Gan To Kagaku Ryoho; 1996 Feb; 23(3):297-302. PubMed ID: 8712822
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2.
Bauer JA; Thompson TA; Church DR; Ariazi EA; Wilding G
Prostate; 2003 May; 55(3):159-67. PubMed ID: 12692781
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?
Mueck AO; Seeger H; Huober J
Life Sci; 2004 Jul; 75(10):1205-10. PubMed ID: 15219808
[TBL] [Abstract][Full Text] [Related]
14. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
Moffatt KA; Johannes WU; Miller GJ
Clin Cancer Res; 1999 Mar; 5(3):695-703. PubMed ID: 10100724
[TBL] [Abstract][Full Text] [Related]
15. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells.
Cho YL; Christensen C; Saunders DE; Lawrence WD; Deppe G; Malviya VK; Malone JM
Cancer Res; 1991 Jun; 51(11):2848-53. PubMed ID: 2032225
[TBL] [Abstract][Full Text] [Related]
18. [Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice].
Fujita F; Fujita M; Inaba H; Sugimoto T; Okuyama Y; Taguchi T
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2263-70. PubMed ID: 1929447
[TBL] [Abstract][Full Text] [Related]
19. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
Chen Z; Koeneman KS; Corey DR
Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
[TBL] [Abstract][Full Text] [Related]
20. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
